Market Overview

UPDATE: Deutsche Bank Raises PT on Tenet Healthcare Corp. on Continued Good Outlook

Share:
Related THC
The Top 20 Wall Street Analysts Of 2015
Credit Suisse On Managed Care: Starts Centene, UnitedHealth And Others At Outperform, WellCare At Underperform

In a report published Friday, Deutsche Bank reiterated its Buy rating on Tenet Healthcare Corp. (NYSE: THC), and raised its price target from $43.00 to $46.00.

Deutsche Bank noted, “We continue to believe an upside risk to THC's valuation is its Conifer segment, which is growing at a faster pace than the overall enterprise and could begin to differentiate THC's multiple once Conifer's stand-alone (non-THC) EBITDA is convincing enough to the market. Finally, we note that our valuation framework does not include THC's NOL, which provides an additional $3-4 of cushion to the valuation. Key risks include: Medicare/Medicaid cuts, implementation risks of PPACA, HCIT conversions, M&A integration, state exposures in Texas, Florida and California.”

Tenet Healthcare Corp. closed on Thursday at $41.76.

Latest Ratings for THC

DateFirmActionFromTo
Jan 2016Mizuho SecuritiesUpgradesNeutralBuy
Jan 2016Wells FargoDowngradesOutperformMarket Perform
Dec 2015Credit SuisseInitiates Coverage onNeutral

View More Analyst Ratings for THC
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (THC)

Get Benzinga's Newsletters